Hill's Pet Nutrition announced that it recently published the first 2025 World of the Cat Report. The report is a 28-page resource offering insight on global cat demographics, advances in feline food, new feline treatments and diagnostics tests, the impact of veterinary care costs, and more. The new resource comes at a time when the need for feline-focused veterinary care is on the rise, according to the Veterinary Medical Association (AVMA).

Cats: The stragglers in veterinary medicine

Cat ownership worldwide has been steadily increasing over the past few decades, with the number of cat-owning households in the US growing from 27 million in 1996 to 42.3 million by 2024.

 According to the 2025 World of the Cat Report, China has an estimated 53 million pet cats. Russia trails behind with about 23 million pet cats, with 59% of Russians owning a cat, making Russia the country with the highest share of cat owners in the world.

The US, meanwhile, is home to the highest number of domesticated cats in the world, with approximately 74 million of these felines.

 Currently, 1 in 3 households in the US has a cat.

 Despite the high number of cat ownership, cats continue to be the underdogs when it comes to veterinary care, with feline medicine lagging behind canine research.

Previously, it was common for veterinarians to treat cats as smaller versions of dogs, using tests and treatments designed for dogs, for feline patients, according to a report by 

 Even students in veterinary school received training that was based on the standard model of the dog.

Still, cats have a different response to drugs compared to dogs, with some drugs having a toxic effect on these felines.

 For example, drugs relying on metabolic conjugation, such as aspirin, propofol, acetaminophen, and carprofen, are cleared more slowly in cats than in dogs.

 Piroxicam, meanwhile, which is metabolized primarily by oxidation, is eliminated faster in cats than in dogs.

 Additionally, the elimination of half-life values for metabolized drugs—oxidized and/or conjugated drugs—varies between cats and dogs.

Although research in feline medicine has progressed in the past years, this area of veterinary medicine is “still considered a bit of a niche interest,” Karen Lisette Perry, BVM&S, CERTSAS, DECVS, MRCVS, MSC Vet Ed, FFCP-I, professor of feline medicine and associate professor of orthopedic surgery at the Michigan State University College of Veterinary Medicine said in a 

 met with Sandra Koch, DVM, MS, DACVD, professor at the University of Minnesota College of Veterinary Medicine and director of the school’s Veterinary Medical Center Dermatology Service, to talk about 

—a recently proposed name for environmental allergies or atopic dermatitis in cats. In the interview, Koch raised one issue feline medicine is facing: a lack of options for treating cats for skin conditions compared to dogs. “Research is moving very slowly in the understanding of the pathogenesis of this condition in cats compared [to] dogs. And if we don't understand the disease very well, it becomes more of a challenge to treat, right?” Koch said, highlighting the need for more research in feline medicine.

The inaugural 2025 World of the Cat Report is Hill’s first feline-focused comprehensive effort, according to the AVMA. The report stems from Hill's' Cat Advisory Team (CAT)—an initiative formed in 2024 as a response to the need for resources focused on feline medicine and research.

“With the rise in feline ownership comes a rise in the need for feline-focused veterinary care,” David Quinter, regional sales director at Hill’s said in an AVMA report.

 “The biggest takeaway from the report is the need for veterinary health care teams to feel equipped with feline-focused resources and tools to help with the increased demand in feline care.”

According to the report, only 40% of pet owners take their cats to the veterinarian each year. Meanwhile, 82% of dogs visit the veterinarian annually. The report suggests the stress cats and clients experience from veterinary visits may play a role in fewer pet owners seeking veterinary care for their cats.

Tips for making veterinary visits less stressful for patients

Additionally, the top conditions diagnosed in cats are gastrointestinal disease, dental disease, urinary tract disease (both upper and lower), upper respiratory tract diseases, obesity/being overweight, kidney disease, and behavior concerns.

 The report also notes that the feline immunodeficiency and feline leukemia viruses remain the 2 most common feline infectious diseases globally.

Among the content in the report are mentions of new feline-specific textbooks, as well as one that will be released in 2026; various new lab tests; the new oral hypoglycemic agents bexagliflozin and velagliflozin, which are sodium-glucose cotransporter-2 (SGLT2) inhibitors; recent Feline Veterinary Medical Association/International Society of Feline Medicine guidelines; accredited Cat Friendly Practices; and the antiviral drug GS-441524 for treating feline infectious peritonitis.

Hill’s has plans to release updated World of the Cat reports each year with the goal of developing a reference guide on feline nutrition and behavior materials. The move comes as the company embraces a “feline-first” attitude, according to the AVMA.

“Feline-first approaches not only get felines in the door but keep them coming back, allowing for effective preventive care and the early detection of common conditions,” said Quinter in an AVMA report.

Do you know a feline veterinarian who goes above and beyond for patients, clients, and the veterinary team? Nominate them for dvm360's 2025 Veterinary Heroes® Awards! These awards honor veterinary professionals, including those specializing in feline medicine, who makes a meaningful impact on patient outcomes through exceptional communication, compassion, and dedication. Submit your nomination

2025 Hill’s Pet Nutrition World of the cat report. Hill’s Pet Nutrition. Accessed April 16, 2025. 

https://na.hillsvna.com/en_US/resources-2/view/244

Won C. Hill’s releases inaugural global cat report amid push to focus on felines. American Veterinary Medical Association. April 2, 2025. Accessed April 16, 2025. 

https://www.avma.org/news/hills-releases-inaugural-global-cat-report-amid-push-focus-felines

Pet population continues to increase while pet spending declines. American Veterinary Medical Association. October 10, 2024. Accessed April 16, 2025. 

https://www.avma.org/news/pet-population-continues-increase-while-pet-spending-declines

Anthes E. Why are cats such a medical black box? 

March 11, 2025. Accessed April 16, 2025. 

https://www.nytimes.com/2025/03/11/science/cats-veterinarians-health.html

Court MH. Feline drug metabolism and disposition. 

Veterinary Clinics of North America: Small Animal Practice

. 2013;43(5):1039-1054. doi:10.1016/j.cvsm.2013.05.002

Bautista-Alejandre A, Koch S. Treatment options for cats with feline atopic skin syndrome. 

. March 13, 2025. Accessed April 16, 2025. https://www.dvm360.com/view/treatment-options-for-cats-with-feline-atopic-skin-syndrome

Articles

The inaugural 2025 World of the Cat Report highlights the latest advances in feline diagnostic tests and treatments, food, statistics, and more

New global cat report released as feline medicine continues to lag behind its canine counterpart

Christopher Pachel, DVM, DACVB, CABC (IAACB), discusses one way to help calm a canine patient in fear.

Creating safe spaces to mitigate fear in dogs

Discernible objects or situations such as thunderstorms, fireworks or other sudden and loud noises can trigger phobia, distress and a behavioral reaction in a pet. Christopher Pachel, DVM, DACVB, CABC (IAACB), a practitioner at the Animal Behavior Clinic in Portland, Oregon, offered a variety of phobia and anxiety intervention strategies while presenting an educational session at the 

2025 Fetch dvm360 Conference in Charlotte

, North Carolina. The lecture included discussion of pets that may need spaces that they feel safe in, such as a quiet area with bedding or other comfort items. In a 

interview recorded at the conference, Pachel further discussed the need for safe spaces as one way to help calm a patient experiencing fear.

Understanding phobia and anxiety in patients

The following is a transcript of the video:

Christopher Pachel, DVM, DACVB, CABC (IAACB

 “Being able to access safety, whatever that means for the animal, and to have a sense of agency, to be able to make some choices, to be able to choose that, addresses both the exposure level, to be able to help them manage that situation, that noise, that stimulus, more effectively. The ability to have some agency and choice actually helps to address some of the anxiety components. What we find is that by giving animals the ability to choose between options that are meaningful for them—in this case, talking about meaningful because of safety or reduced exposure—that actually addresses some of the anxiety component. So we're coming at it from multiple angles. And what I love about really helping caregivers to understand what the animals needs are is they said, ‘Well, what do I do? What's going to make my pet feel better?’ And the honest answer is, ‘let's ask your dog. Let's ask your cat. Let's observe them.’

“I remember one particular case, which was a noise phobia case, and the owner said, ‘I don't know why, but in the storm noises, when we have fireworks, the dog always comes here’—and they pointed to a space just in the middle of their basement family room—'always here.’ And we said, ‘well, I don't know why.’ So, because I'm weird and I don't mind being awkward, I'm like, ‘Cool. Let me get down at your dog's level.’ And I'm down on my hands and knees in the middle of their living room. And I have no idea how to explain it from an acoustic standpoint, but it was like a little dead zone right there. And once you got into this 3 by 3 space, you could just kind of feel the reverberations of noises getting really, really muffled. The dog is clearly going to be able to recognize that and know that ‘I feel better here,’ rather than any other space. And so simply observing, they didn't know why yet, but observing that this is where my dog feels more comfortable, let's make sure they have access to that, and let's see why that might be meaningful. Can we replicate that? So then having that knowledge that, okay, your dog is more comfortable when their acoustics are buffered. Let's see if we can layer that into so many other scenarios as a way to, again, give them that sense of safety and control and agency.”

Videos

Christopher Pachel, DVM, DACVB, CABC (IAACB), a practitioner at the Animal Behavior Clinic in Portland, Oregon, discusses one way to help calm an animal that's afraid.

Creating safe spaces to mitigate fear in pets

Pet owners living with senior pets or a pet with a terminal disease often come to their veterinarian asking, “When is it time?” or “How will I know when it’s time to euthanize?”. There is not a one-size-fits-all answer to this question. As veterinarians, it is our duty to respond compassionately and provide owners with the education and tools they need to assess their pet’s quality of life. During a recent session at the Fetch dvm360 Conference in Charlotte, North Carolina, Leigh Ann Collins, DVM, CVA, CPEV, regional veterinary director with Lap of Love, discussed strategies veterinarians can use to help their clients with this difficult assessment.

In many disease processes, there is not an obvious time when euthanasia becomes appropriate. Instead, there is often a range of time during which euthanasia is appropriate, depending on the individual pet and family. Collins suggested that veterinarians discuss 4 factors with clients to help them answer the question of “When is it time?”: ailment, family beliefs, pet personality, and budgets.

“Every disease is different,” Collins said, and death looks different in each. Veterinarians must educate clients on the disease process their pet is experiencing and set expectations for how the disease will progress and what they may expect. Conversations will look different depending on the disease process as well.

In general, diseases can be divided into 3 categories:

Imminent, such as a hemoabdomen or respiratory distress, where a decline happens quickly and often does not allow families to plan for euthanasia or schedule in-home care.

Intermediate, such as heart failure, where there will be ups and downs over time. Some changes can happen quickly.

Non-imminent, such as chronic kidney disease or osteoarthritis, where the decline is slow and families will have time to plan for end-of-life care, including scheduling euthanasia or utilizing an in-home euthanasia service.

Collins likened imminent diseases to a cliff, whereas intermediate diseases are a winding road, and non-imminent are a slow fade. Identifying which category of disease a pet family is facing can help frame the conversation around quality of life and euthanasia.

Euthanasia is an emotional decision for families and can be impacted by many factors. This includes cultural and/or religious beliefs, personal experiences, relationship with the individual pet, and the pet’s use, which is a particularly important factor for working animals. Collins encouraged veterinary teams to ask questions if you aren’t sure how a family’s beliefs are affecting their decision.

Collins encouraged veterinarians and pet owners to consider this question: “Just because there are options [for treatment], is it appropriate for the pet?” Families should consider how easy treatment will be and what their pet’s tolerance for medication, diet change, recheck veterinary appointments, and other treatment considerations may be. Treatment plans should be tailored to the individual pet’s personality. Although some pets may tolerate strict rest for medical management of intervertebral disc disease in dogs or subcutaneous fluids for chronic kidney disease, others could be extremely stressed. This will impact not only the pet’s quality of life but the relationship between pet and client.

The last factor to consider includes the family’s budgets. Although finances are often a factor, there are other budgets that need to be considered, including:

Physical ability to medicate and provide nursing care

Time to perform treatments like bathing or maintain a medication schedule

Caregiver burden can be experienced when caring for a sick pet and may be influenced by many factors including caregiving responsibilities for other pets or human family members as well as past experiences with sick pets. Collins encouraged veterinary teams to ask questions about clients’ previous experiences with euthanasia and end-of-life decisions to guide conversations about the current pet.

Objective approaches to measure quality of life

In Collins’ experience, “the [pet owner] who is doing the majority of the caretaking comes to the decision to euthanize first.” However, other family members may have differing opinions, and it is important that veterinarians compassionately guide the family through the decision-making process. Often, this starts with a discussion of assessing a pet’s quality of life.

Quality of life can be difficult to define and often looks different for each individual pet and family. Six major categories can be considered: mobility, hydration, appetite, hygiene, happiness, and pain. Collins noted that there are also many sensations that can detract from a pet’s quality of life, including physical pain, nausea, pruritus, breathlessness, thirst, and hunger. Additionally, social and emotional factors like anxiety or phobias, fear, isolation, loneliness, boredom and frustration, and stress can have major negative effects on quality.

Ultimately, we must find a way to measure a subjective concept. Collins encourages veterinary teams to give owners ways to evaluate quality of life at home and not assume that pet families know how to do this. Some common strategies for measuring quality of life include:

Make a list of the pet’s 5 favorite things to do and assess if they are still able to do them.

Consider things the pet hates/dislikes and determine if they are still reacting in the same way to these events (ie, mail delivery, thunderstorms).

Assess whether the pet still has their five freedoms, as defined by the ASPCA: freedom from hunger and thirst, freedom from discomfort, freedom from pain, injury or disease; freedom to express normal behavior, and freedom from fear and distress.

Quantify good and bad days on a calendar or with colored marbles in a jar. This requires families to agree on how they define “good” and “bad” and what percentage of the day needs to fall into the category.

Provide quality of life assessments to owners. There are numerous tools available including Lap of Love resources (quality of life scale, calendar, daily assessment), the Ohio State University’s quality of life scale, and Dr. Alive Villalobos’ H5M2 scale.

Make a bucket list of experiences for the pet to celebrate their life together.

Encourage families to compare videos or pictures over time to see how the pet’s appearance and activity compares to previous times.

At times, pet families may not see how bad things are, even when it seems obvious to us as veterinary professionals. It is essential that we avoid judgment during these conversations. Collins suggested that veterinarians start by discussing the disease process and setting expectations for how the disease will progress, including what death without assistance will look like. She also encouraged owners to set a “line in the sand” that they would not want to cross, such as their pet entering respiratory distress or being unable to stand.

Another approach is to have the owner do a quality of life scale in the office and compare their answers to one filled out by the veterinarian. Ultimately, end-of-life decisions belong to the pet family. Veterinarians can discuss the family’s beliefs, concerns, and fears to determine how best to help both the pet and family. Veterinarians should consider the pet’s condition and prescribe pain and sedation as needed to maximize the pet’s comfort.

“In traditional general practice, we don’t have as much time to have these conversations,” Collins noted. General practitioners should be aware of resources for pet owners to help with anticipatory grief and consider referring clients to a hospice and palliative care veterinarian to continue the end-of-life conversations, often in the home environment.

When guiding owners through end-of-life decision making, assessing quality of life is an essential component. Veterinarians should maintain compassion and withhold judgment throughout the process while educating owners and providing tools clients can use to objectively assess their pet’s quality of life.

, is a 2013 graduate of the University of Pennsylvania in Philadelphia, a practicing veterinarian, and freelance speaker and author in western Pennsylvania. She is passionate about mentorship, spectrum of care, and addressing common sources of stress for veterinary teams and recent graduates. Outside of clinical practice, Boatright is actively involved in organized veterinary medicine.

Collins L. Helping owners with assessing quality of life. Presented at dvm360 Fetch Charlotte 2025: Charlotte, NC. March 16, 2025.

Five freedoms. ASPCA. Accessed April 16, 2025. 

https://www.aspca.org/sites/default/files/upload/images/aspca_asv_five_freedoms_final1.ashx_.pdf

Helping owners assess their pet’s quality of life is an important part of the end-of-life decision making process

Guiding pet owners through end-of-life decision-making

Ellen Behrend, VMD, PhD, DACVIM, talks about what a sodium-glucose cotransporter-2 inhibitor is

Understanding the physiology behind SGLT2 inhibitors 

, Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), past faculty of Auburn University College of Veterinary Medicine and a current consultant at Veterinary Information Network, an online community and resource center for veterinarians, explains what a sodium-glucose cotransporter-2 (SGLT2) inhibitor is. Behrend, who specializes in small animal endocrinology, noted that this new class of oral medications have “revolutionized” the treatment of type 2 diabetes in humans and is now being used in veterinary medicine.

Currently, SGLT2 inhibitors are used in cats only as single agents for diabetes. In the video, Behrend goes into detail on how these medications work to decrease blood glucose concentrations in feline patients with diabetes.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM): 

I'm Ellen Behrend. I am a board-certified small animal internist with a special interest in small animal endocrinology. I spent the majority of my career as a faculty member at Auburn University, and I now am a consultant for Veterinary Information Network.

[SGLT2 inhibitors] are drugs that have revolutionized the treatment of type 2 diabetes in people, and they're relatively new to veterinary medicine. We use them in cats only as single agents for diabetes.

SGLTs are a class of molecules that transport glucose across membranes. SGLT2 is mainly in the kidneys.

So, remember from physiology that glucose is freely filtered at the glomerulus and then the body in a normal dog, cat, human, typically reabsorbs pretty much all of the glucose, so there's no glucose in the urine. An SGLT2 inhibitor inhibits that. So, it stops the reabsorption of glucose from the renal tubules, meaning that the glucose is going to then be excreted through the urine instead, and by getting rid of all of that glucose in the urine, that's how SGLT2 inhibitors decrease blood glucose concentrations in diabetics.

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), describes a sodium-glucose cotransporter-2 inhibitor in a dvm360 interview.

You might expect innovation and disruption to be prominent in veterinary dentistry, considering that periodontal disease has been a prevalent health issue in dogs and cats for as long as we can remember. Fortunately, a shift has occurred: We now embrace inflammation as the primary trigger for periodontal disease instead of bacteria, leading to new strategies for prevention and treatment.

Hyaluronic acid (HA) was initially recognized for its applications in human orthopedics, ophthalmology, and wound healing. It is poised to become an advancement in veterinary dentistry for treating periodontal disease and improving oral surgical site recovery in pets.

Evidence-based, peer-reviewed studies have shown that a single dose of HA after a procedure accelerates tissue healing, enhances bone formation, and reduces probing pocket depth in various dental settings. The use of HA in veterinary dentistry is significant because of the following:

HA targets the underlying inflammation responsible for periodontal disease.

HA may slow the progression to more advanced periodontal

This shift toward using HA represents a more holistic and less invasive approach to managing pet periodontal disease. It also aligns with the increasing understanding of inflammation’s role in the condition and moves away from antibiotic-based interventions.

Understanding the challenge: Periodontal disease in companion animals

Periodontal disease remains one of the most prevalent health issues in veterinary practice, affecting approximately 80% of dogs and 70% of cats by 3 years of age.

 If left untreated, it can lead to progressive tissue destruction, chronic pain, systemic inflammation, and organ damage. Although traditional methods such as mechanical debridement, adjunctive therapies, and, ultimately, extractions continue to be the standard treatments, the increasing demand for more biocompatible solutions calls for innovative interventions.

What is HA, and why is it relevant in veterinary dentistry?

HA is a naturally occurring glycosaminoglycan found in extracellular matrices, synovial fluid, and soft tissues.

 Its hydrophilic properties enable it to retain moisture and encourage cellular migration, making it a component in tissue regeneration and repair. HA has been successfully integrated into treatment protocols for periodontitis, postextraction healing, and implantology in human dentistry.

 Its potential for veterinary applications is being explored through previously published studies showing significant benefits in managing periodontal disease in dogs and cats.

The primary advantages of HA in veterinary dentistry include the following:

Enhancing angiogenesis and tissue regeneration

By incorporating HA-based therapies into routine dental care, veterinarians can provide a multimodal approach to managing periodontal disease, ultimately enhancing clinical outcomes and patient comfort.

Angiogenic benefits of HA in oral wound healing

One of HA’s contributions to veterinary dentistry is its ability to stimulate angiogenesis, which encourages tissue repair and accelerates postsurgical healing. HA’s proangiogenic effects are advantageous because impaired blood vessels lead to the progression of periodontal disease.

promoting endothelial cell migration and proliferation, enhancing capillary formation in damaged periodontal tissues;

improving oxygen and nutrient delivery, ensuring adequate support for regenerative processes; and

accelerating healing after surgery, especially at extraction sites, gingival flaps, and during grafting procedures.

The studies on dogs indicate that applying HA-based gels topically after dental procedures shortens healing time and enhances mucosal integrity. Additionally, HA emerged as a valuable adjunctive treatment for chronic periodontal issues and recovery after extractions. The 5 canine studies referenced in this article include histologic confirmation of the positive effects of HA on periodontal disease of varying severity, including gingival recession,

 Each of these studies reported statistically significant improvements in several end points, such as the regeneration of bone, periodontal ligament, and cementum.

Anti-inflammatory properties of HA in periodontal therapy

Inflammation is a key factor in the pathology of periodontal disease, as bacterial biofilms often provoke an extreme immune response that results in gingival destruction and alveolar bone loss.

 HA alleviates inflammatory damage through several mechanisms, including the following:

Regulation of cytokine activity: HA modulates the release of key inflammatory mediators, such as tumor necrosis factor-α, IL-1β, and IL-6, reducing excessive immune activation.

Inhibition of matrix metalloproteinases (MMPs)1: HA inhibits the activity of MMPs, which break down extracellular matrix components and contribute to the degradation of the periodontal ligament.

Enhancing tissue hydration and lubrication: HA maintains mucosal hydration by binding to water molecules, reducing tissue irritation, and promoting healing.

Antimicrobial properties: HA’s role in controlling oral pathogens

Another aspect of HA use in veterinary dentistry is its intrinsic antimicrobial activity. The oral cavity harbors a diverse microbiome, and dysbiosis plays a key role in developing periodontal disease. HA exhibits antimicrobial effects through multiple mechanisms, including the following:

Direct bacteriostatic action: HA disrupts bacterial cell membranes, particularly in periodontal pathogens such as 

Biofilm disruption: HA hinders bacterial adhesion and biofilm formation, decreasing plaque buildup and gum inflammation.

Synergy with other antimicrobial agents: HA enhances the efficacy of antiseptics such as chlorhexidine and essential oils, making it a valuable adjunct in plaque-control strategies.


With increasing concerns regarding antibiotic resistance, HA presents a nonantibiotic antimicrobial aid for managing periodontal infections, reducing bacterial load, and supporting a healthier oral environment.

Analgesic effects of HA in veterinary dental procedures

Pain management is a vital aspect of veterinary dentistry, as ignoring oral pain can severely affect an animal’s quality of life. HA possesses intrinsic analgesic properties, making it especially effective for decreasing pain related to periodontal disease and oral surgery. The following includes the ways in which HA provides pain relief:

Modulating pain receptors: HA interacts with nerve endings, reducing nociceptive signaling and discomfort.

Promoting soft tissue healing: Quicker tissue repair leads to less inflammation and extended pain relief after surgery.

Demonstrating localized analgesic effects: Clinical studies in human dentistry showcase HA’s effectiveness in alleviating postprocedural pain, a benefit that is now being used in veterinary applications.

Clinical applications of HA in veterinary dentistry

HA is available in various veterinary formulations, including oral gels, mouth rinses, and injectable solutions. I am currently using the gel formulation for the following:

Periodontal disease management: HA gels applied to gingival pockets after scaling and root planing help reduce inflammation and promote tissue regeneration. (

Postextraction care: HA minimizes the risk of alveolar osteitis (dry socket in humans) and accelerates healing. (

Wound healing after oral surgery: HA-based formulations enhance mucosal recovery following gingival flap surgery and tumor excision.

Integrating HA into veterinary dental protocols

Despite its promising benefits, HA’s use in veterinary dentistry remains underutilized because of limited awareness and product availability. However, innovative formulations, such as the HA-based gel formulated for veterinary use, offer veterinarians a practical tool for incorporating HA into standard dental care protocols.

As more clinical trials validate the efficacy of HA in veterinary dentistry, we anticipate a broader adoption of HA-based therapies. Future research should concentrate on the following:

Optimizing application protocols for periodontal treatments

Assessing the long-term impacts of HA on periodontal health

Developing combination therapies with existing dental treatments

HA is an advanced treatment for periodontal disease in dogs and cats. Its angiogenic, anti-inflammatory, antimicrobial, and analgesic properties make it a valuable tool for veterinarians committed to enhancing patient outcomes. As veterinary dentistry progresses, incorporating HA-based products into practice presents a promising opportunity to improve oral health and overall patient well-being.

Jan Bellows, DVM, DAVDC, DABVP (Canine, Feline), FAVD

received his doctorate in veterinary medicine from Auburn University in Alabama. After completing an internship at the Animal Medical Center in New York, New York, he moved to Florida, where he practices companion animal medicine surgery and dentistry at All Pets Dental in Weston.

Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. 

. 2007;465:241-248. doi:10.1097/BLO.0b013e31815873f9

Enlund KB, Brunius C, Hanson J, et al. Dental home care in dogs - a questionnaire study among Swedish dog owners, veterinarians and veterinary nurses. 

. 2020;16(1):90. doi:10.1186/s12917-020-02281-y

Kirkwood J, Newman S, Whittemore M. Dental disease and oral health in dogs. 

. 2010;27(1):25-30. doi:10.1053/j. jdsci.2010.01.002

Caton J. Biological and measurement issues critical to design of gingivitis trials. 

. 1992;27(4 Pt 2):364-374. doi:10.1111/j.1600-0765.1992.tb01697.x

Miglani A, Vishnani R, Reche A, Buldeo J, Wadher B. Hyaluronic acid: exploring its versatile applications in dentistry. 

. 2023;15(10):e46349. doi:10.7759/cureus.46349

Eliezer M, Imber JC, Sculean A, Pandis N, Teich S. Hyaluronic acid as adjunctive to non-surgical and surgical periodontal therapy: a systematic review and meta-analysis. 

. 2019;23(9):3423-3435. doi:10.1007/ s00784-019-03012-w

Ostos-Aguilar BI, Pinheiro Furquim C, Muniz FWMG, Faveri M, Meza-Mauricio J. Clinical efficacy of hyaluronic acid in the treatment of periodontal intrabony defect: a systematic review and meta-analysis. 

. 2023;27(5):1923-1935. doi:10.1007/s00784-022-04855-6

Gegout PY, Stutz C, Huck O. Gels as adjuvant to non-surgical periodontal therapy: a systematic review and meta-analysis. 

. 2023;9(7):e17789. doi:10.1016/j.heliyon.2023.e17789

Dababseh D, Altell R, Kang J, et al. Adjunctive use of hyaluronic acid in non-surgical periodontal therapy: a systematic review and meta-analysis. 

. 2025;155:105613. doi:10.1016/j. jdent.2025.105613

Kawano Y, Patrulea V, Sublet E, et al. Wound healing promotion by hyaluronic acid: effect of molecular weight on gene expression and in vivo wound closure. 

). 2021;14(4):301. doi:10.3390/ph14040301

Lajeunesse D, Delalandre A, Martel-Pelletier J, Pelletier JP. Hyaluronic acid reverses the abnormal synthetic activity of human osteoarthritic subchondral bone osteoblasts. 

. 2003;33(4):703-710. doi:10.1016/S8756-3282(03)00206-0

Ibrahim Almusi BJ, Al-Kamali RK. Effect of platelet-rich fibrin combined with hyaluronic acid on bone formation in dental implant sockets: an in vivo study in sheep. 

. 2024;16(7):e64651. doi:10.7759/cureus.64651

de la Peña E, Sala S, Rovira JC, Schmidt RF, Belmonte C. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. 

. 2002;99(3):501-508. doi:10.1016/S0304-3959(02)00260-9

Shirakata Y, Nakamura T, Kawakami Y, et al. Healing of buccal gingival recessions following treatment with coronally advanced flap alone or combined with a cross-linked hyaluronic acid gel: an experimental study in dogs. 

. 2021;48(4):570-580. doi:10.1111/jcpe.13433

Tella EA, Aldahlawi SA, Azab ET, Yaghmoor WE, Fansa HA. Evaluation of hyaluronic acid gel with or without acellular dermal matrix allograft in the treatment of class II furcation defects in dogs: a histologic and histomorphometric study. 

. 2023;35(7):845-853. doi:10.1016/j. sdentj.2023.07.007

Shirakata Y, Imafuji T, Nakamura T, et al. Cross-linked hyaluronic acid gel with or without a collagen matrix in the treatment of class III furcation defects: a histologic and histomorphometric study in dogs. 

. 2022;49(10):1079-1089. doi:10.1111/jcpe.13694

Shirakata Y, Imafuji T, Nakamura T, et al. Periodontal wound healing/regeneration of two-wall intrabony defects following reconstructive surgery with cross-linked hyaluronic acid-gel with or without a collagen matrix: a preclinical study in dogs. 

. 2021;52(4):308-316. doi:10.3290/j. qi.b937003

Kim JJ, Song HY, Ben Amara H, Kyung-Rim K, Koo KT. Hyaluronic acid improves bone formation in extraction sockets with chronic pathology: a pilot study in dogs. 

. 2016;87(7):790-795. doi:10.1902/jop.2016.150707

Jegasothy SM, Zabolotniaia V, Bielfeldt S. Efficacy of a new topical nano-hyaluronic acid in humans. 

Romanò CL, De Vecchi E, Bortolin M, Morelli I, Drago L. Hyaluronic acid and its composites as a local antimicrobial/ antiadhesive barrier. 

. 2017;2(1):63-72. doi:10.7150/jbji.17705

25. Harrer D, Sanchez Armengol E, Friedl JD, et al. Is hyaluronic acid the perfect excipient for the pharmaceutical need? 

. 2021;603:120589. doi:10.1016/j.ijpharm.2021.120589

Gotoh S, Onaya J, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. 

. 1993;52(11):817-822. doi:10.1136/ard.52.11.817

The disruptive and innovative roles of hyaluronic acid in managing dog and cat dental disease